On the 30 September 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,113 million and NAV per share was SEK 35.91. Return on NAV per share in the month was -6.8%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 4.01 | 11.2% |
| Prokarium | 50% | 296 | 3.41 | 9.5% |
| Atrogi | 47% | 215 | 2.48 | 6.9% |
| KAHR Medical | 34% | 214 | 2.47 | 6.9% |
| Microbiotica | 10% | 191 | 2.20 | 6.1% |
| Bonsai Biotherapeutics | 100% | 158 | 1.82 | 5.1% |
| AnaCardio | 9% | 105 | 1.22 | 3.4% |
| Mendus | 22% | 89 | 1.03 | 2.9% |
| Xintela | 60% | 88 | 1.02 | 2.8% |
| Xspray Pharma | 17% | 85 | 0.98 | 2.7% |
| Geneos Therapeutics | 12% | 71 | 0.82 | 2.3% |
| EpiEndo Pharmaceuticals | 9% | 56 | 0.65 | 1.8% |
| Vitara Biomedical | 9% | 51 | 0.58 | 1.6% |
| Egetis Therapeutics | 1% | 43 | 0.50 | 1.4% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.38 | 1.1% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.4% |
| Strike Pharma | 18% | 11 | 0.12 | 0.3% |
| Empros Pharma | 79% | 0 | 0.00 | 0.0% |
| Total | 2,065 | 23.82 | 66.3% | |
| Commercial Growth | ||||
| Symcel | 30% | 211 | 2.43 | 6.8% |
| NorthX Biologics | 61% | 202 | 2.33 | 6.5% |
| Chromafora | 29% | 149 | 1.72 | 4.8% |
| Nanologica | 50% | 50 | 0.58 | 1.6% |
| Frontier Biosolutions | 2% | 27 | 0.31 | 0.9% |
| Bohus Biotech | 45% | 22 | 0.26 | 0.7% |
| Total | 661 | 7.63 | 21.2% | |
| Assets and liabilities related to Portfolio companies | 131 | 1.51 | 4.2% | |
| Other assets and liabilities | 256 | 2.95 | 8.2% | |
| Net Asset Value | 3,113 | 35.91 | 100.0% | |